Latest Breaking News On - Sylvia wheeler - Page 6 : comparemela.com

Laguna Tech USA Announces Site Record Number of Transcatheter Heart Valves Implanted at Single Center on Same Day in First-in-Human Clinical Trial

Laguna Tech USA Announces Site Record Number of Transcatheter Heart Valves Implanted at Single Center on Same Day in First-in-Human Clinical Trial
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Christian dauvergneSylvia wheelerUniversity of virginiaCorporate affairsTranscatheter heart valves implantedSingle centerSame dayFirst in human clinicalInstituto nacional de toraxEtech united statesExpandable aortic valve systemInterventional cardiologyScott limGilbert madridLaguna tech unitedLaguna tech united states

RAPT Therapeutics to Present at the 42nd Annual J P Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small.

Brian wongAljanae reynoldsSylvia wheelerTherapeutics incChief executive officerHealthcare conference

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

NEEDHAM, Mass., Dec. 12, 2023 Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,.

United statesSylvia wheelerAljanae reynoldsSociety for immunotherapy of cancerDrug administrationCompany nasdaqCandel therapeutics incNational cancer instituteFast track designationPaul peter takDiscovery platformNon metastatic pancreaticSpecial protocol assessmentPancreatic ductal adenocarcinomaEnd resultsTrack designation

Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)

Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSylvia wheelerCoryr nicholasElizabeth wolffeDavid blumCenters for diseaseCalifornia institute for regenerative medicineMeeting of the american epilepsy societyAmerican epilepsy societyTherapeutics presents new clinical dataFirst cohortOngoing phaseLabel trialDrug resistant mesial temporal lobe epilepsyAnnual meetingData safety monitoring board

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 01, 2023 Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms,.

United statesSylvia wheelerAljanae reynoldsTempest therapeutics incCompensation committeeMedia contacts